⚠️ The post-ibogaine period carries serious, documented medical risks — including delayed cardiac events, acute relapse with fatal overdose potential, and psychological crisis — that extend well beyond the acute treatment window. Do not treat discharge from a clinic as medical clearance. Active monitoring, lifestyle protocols, and professional support for a minimum of 90 days are not optional extras; they are core components of safe ibogaine care.

Post-Ibogaine Integration: A Practical 90-Day Guide

Ibogaine treatment is not complete when the acute experience ends. The substance's primary active metabolite, noribogaine, has a half-life of 24–96 hours and remains pharmacologically active — including effects on cardiac ion channels — for days after dosing (Glue et al., 2015). Meanwhile, the neuroplastic window opened by ibogaine, sometimes described in clinical literature as a period of heightened synaptic remodeling, offers a brief but powerful opportunity to consolidate psychological and behavioral change. Missing that window, or ignoring the medical risks that accompany it, accounts for a significant share of adverse outcomes.

This guide is organized into three phases: Days 1–30 (acute recovery), Days 31–60 (consolidation), and Days 61–90 (stabilization). Each phase includes specific medical precautions, psychological practices, relapse-prevention protocols, and lifestyle requirements grounded in published research and clinical protocols used at accredited ibogaine facilities.

Understanding What Has Changed in Your Body

Before reviewing the timeline, it is important to understand the physiological context you are working within immediately after treatment.

Cardiac Status

Ibogaine prolongs the cardiac QTc interval — the electrical recovery time of the heart — in a dose-dependent manner. A QTc above 500 ms is considered a high-risk threshold for potentially fatal arrhythmias including Torsades de Pointes (Koenig et al., 2015). This prolongation can persist for 24–72 hours after the acute experience. Any reputable clinic will conduct a post-treatment ECG before discharge, but QTc should ideally be confirmed below 450 ms (men) or 460 ms (women) before you are cleared. If your clinic did not provide a discharge ECG, obtain one from a physician within 48 hours of leaving the facility — do not wait.

Beyond QTc, ibogaine's effects on hERG potassium channels and sodium channels mean that the cardiac risk period extends into the first week post-treatment. Specific drugs that must not be taken during this period because they compound QTc prolongation include: methadone, antipsychotics (haloperidol, quetiapine, risperidone), fluoroquinolone antibiotics (ciprofloxacin, levofloxacin), azithromycin, certain antifungals (fluconazole), ondansetron (Zofran), and many antidepressants including SSRIs at higher doses. A full list is maintained at CredibleMeds.org. Show this list to any treating physician or emergency provider in the weeks after treatment.

Neurochemical Status

Ibogaine acts on multiple receptor systems simultaneously — opioid, NMDA, sigma, serotonin, and nicotinic acetylcholine receptors. Research on GDNF (glial cell line-derived neurotrophic factor) upregulation in animal models (He et al., 1997) and BDNF modulation suggests ibogaine initiates a neuroplastic remodeling process. Clinically, this means the brain is unusually responsive to new experiences, behaviors, and emotional inputs in the weeks following treatment. This is the mechanism behind ibogaine's reputation for compressing therapeutic timelines — and also why trauma, high stress, or reintroduction of addictive substances during this window can be particularly damaging or entrenching.

Opioid Tolerance

If ibogaine was used to interrupt opioid dependence, your opioid tolerance has been dramatically reduced or eliminated. This is not a gradual reduction — it is abrupt. This single fact is responsible for the majority of ibogaine-related deaths that occur in the weeks after treatment. Returning to a pre-treatment opioid dose — heroin, fentanyl, oxycodone, or any other opioid — at the amount previously used is likely to be fatal. This risk persists for weeks to months as tolerance does not simply return on a predictable schedule. Naltrexone (oral or extended-release injectable Vivitrol) and buprenorphine (in medically supervised protocols) are both evidence-based options that can provide protection during this period; discuss them with an addiction medicine physician before or immediately after treatment.

Phase 1: Days 1–30 — Acute Recovery

Medical Priorities (Days 1–7)

  • ECG within 48 hours of discharge if not performed at the clinic. Confirm QTc is within normal limits.
  • Avoid all QTc-prolonging medications for a minimum of 7 days, preferably 14. If you require psychiatric medication, consult a psychiatrist who has reviewed your treatment records before restarting any psychotropic drug.
  • No alcohol. Alcohol interacts with the ibogaine metabolite noribogaine and independently stresses cardiac conduction.
  • No stimulants — including high-dose caffeine, cocaine, methamphetamine, or MDMA — which increase cardiac demand during a period of potential conduction instability.
  • No opioids of any kind unless under direct medical supervision for pain management, in which case doses must be titrated from zero due to eliminated tolerance.
  • Hydration: Ibogaine can cause significant nausea, vomiting, and perspiration during the acute experience. Electrolyte replacement (not plain water alone) is important in the first 48–72 hours. Oral rehydration salts or electrolyte supplements are appropriate; IV fluids if you cannot keep fluids down.
  • Rest: Ataxia (loss of coordinated movement) and nystagmus (involuntary eye movement) are normal acute effects that typically resolve within 24–48 hours. Do not drive, operate machinery, or make significant decisions while these effects persist.

Sleep (Days 1–14)

Ibogaine reliably disrupts sleep architecture, often eliminating or drastically reducing REM sleep for 3–7 days post-treatment. Some participants report insomnia lasting 2–3 weeks. This is normal but must be managed carefully. Do not use benzodiazepines (diazepam, lorazepam, clonazepam) as sleep aids in this period — they carry dependence risk and interact with the ongoing neuroplastic process. Clinically supported alternatives include low-dose melatonin (0.5–3 mg), magnesium glycinate, and sleep hygiene protocols. If insomnia becomes severe (no sleep for more than 72 hours), contact a physician — this can destabilize mental health.

Psychological Safety (Days 1–30)

The oneirogenic (dream-like) experience of ibogaine frequently surfaces unresolved trauma, grief, and psychological material with unusual vividness. In the week following treatment, this content continues to be processed. It is common — and clinically documented — to experience:

  • Emotional lability (rapid mood shifts)
  • Heightened anxiety or a sense of existential openness
  • Intrusive memories or dream-like waking states
  • Temporary depersonalization or derealization
  • Grief, sometimes without an identifiable object

These states are generally transient but require appropriate support. Specific actions to take:

  • Schedule at least one integration session with a therapist experienced in psychedelic-assisted therapy within the first 7 days. Organizations such as the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS-affiliated training programs have trained a growing network of integration therapists.
  • Establish a daily check-in structure with a trusted person — a sober support, sponsor, family member, or friend — who knows what you have been through.
  • Keep a journal. Writing within 24–48 hours of the experience captures material that fades rapidly, similar to dream recall. This material is often directly relevant to later therapeutic work.

Relapse Prevention Infrastructure (Days 1–30)

Research on ibogaine for opioid use disorder (Brown & Alper, 2018; Noller et al., 2018) consistently shows that the post-treatment period without structured support dramatically increases relapse risk. Ibogaine reduces craving and withdrawal acutely, but it does not eliminate the environmental, psychological, and behavioral triggers that sustained the addiction. Before or immediately after treatment:

  • Remove or distance from substances, paraphernalia, and drug-using contacts from your living environment.
  • Identify your three highest-risk relapse situations and write a specific response plan for each.
  • If you used opioids, discuss naltrexone or buprenorphine with an addiction medicine physician as a pharmacological safety net — not a sign of failure, but a documented life-saving intervention.
  • Connect with peer support: SMART Recovery, NA, AA, Refuge Recovery, or other communities that match your values. In-person attendance is more protective than online-only participation (Kelly et al., 2017).

Nutrition (Days 1–30)

Ibogaine is metabolized by liver CYP2D6 and CYP3A4 enzymes. Support liver function during recovery:

  • Eat whole foods with adequate protein (minimum 0.8g/kg body weight daily for tissue repair).
  • Avoid grapefruit and grapefruit juice — it inhibits CYP3A4 and can interfere with drug metabolism during the noribogaine clearance period.
  • Consider N-acetyl cysteine (NAC) supplementation to support glutathione production, though discuss with a physician if you have liver or kidney concerns.
  • Limit or eliminate alcohol for the full 90 days.

Phase 2: Days 31–60 — Consolidation

By day 30, the acute medical risks have generally resolved for most people (though individual variation exists). The focus now shifts to consolidating behavioral and psychological changes before the neuroplastic window closes — estimated by some researchers at approximately 4–8 weeks post-treatment, though precise timing varies.

Therapy Cadence

Weekly therapy sessions with an integration-informed therapist are the clinical standard during this phase. This is not optional if the goal is durable change. Effective modalities documented in psychedelic integration contexts include:

  • IFS (Internal Family Systems): Particularly well-matched to the parts-based material that often emerges during ibogaine experiences.
  • EMDR (Eye Movement Desensitization and Reprocessing): Indicated when trauma content has surfaced and requires direct processing.
  • CBT and DBT skills: For behavioral habit change and emotional regulation during the vulnerable consolidation period.
  • Somatic approaches: Ibogaine frequently produces body-based memories; somatic experiencing or body-oriented therapies can be complementary.

Physical Exercise

Moderate aerobic exercise supports BDNF production, dopamine regulation, and mood stability — all of which are directly relevant to addiction recovery and neuroplastic consolidation (Cotman & Berchtold, 2002). A practical protocol:

  • Weeks 5–8: 30 minutes of moderate-intensity aerobic activity (brisk walking, swimming, cycling) 4–5 times per week.
  • Avoid high-intensity exercise before Day 14 without medical clearance, particularly if cardiac history is a factor.
  • Add resistance training from Week 6 onward to support metabolic health and mood.

Mindfulness and Meditation

Daily mindfulness practice has Level 1 evidence for relapse prevention in substance use disorders (Mindfulness-Based Relapse Prevention, MBRP; Bowen et al., 2014). During the integration period, a daily 15–20 minute practice also serves as a structured touchpoint with the psychological material opened by treatment. Specific practices that align well with ibogaine integration:

  • Loving-kindness (metta) meditation to address shame, which is frequently surfaced during ibogaine experiences.
  • Body scan meditation to re-establish embodied awareness.
  • Journaling immediately after meditation to capture ongoing integration insights.

Social Reconnection

Social isolation is a major relapse risk factor. Days 31–60 are the appropriate time to systematically rebuild or repair relationships strained by addiction or prior mental health challenges — with therapeutic support, not impulsively. Specific actions:

  • Identify one or two relationships you want to repair. Bring this into therapy before acting.
  • Maintain at minimum two meaningful social contacts per week.
  • Avoid romantic relationships that began within the first 90 days of major recovery work — the 'pink cloud' phenomenon (an artificially elevated mood state) can distort judgment.

Monitoring for Emerging Mental Health Conditions

Ibogaine can unmask or precipitate psychiatric conditions including depression, anxiety disorders, and — rarely but seriously — psychosis or hypomania, particularly in individuals with personal or family history of bipolar disorder or schizophrenia spectrum conditions. Watch for:

  • Persistent low mood or anhedonia lasting more than 2 weeks
  • Sleep changes (too much or too little) that are progressive
  • Racing thoughts, decreased need for sleep combined with elevated energy (potential hypomania)
  • Paranoia, ideas of reference, or perceptual disturbances not clearly tied to the psychedelic experience

If any of these emerge, contact a psychiatrist immediately. Do not self-medicate with cannabis, alcohol, or other substances.

Phase 3: Days 61–90 — Stabilization

The neuroplastic window is beginning to close, but the habits, relationships, and psychological frameworks established during Phases 1 and 2 are becoming more durable. The work now is consolidation and planning for what comes after Day 90.

Psychiatric Medication Review

If psychiatric medications were held before or during ibogaine treatment (which is typically required — see contraindications below), Days 60–90 represent an appropriate window to reassess whether they are needed at all, and if so, at what dose. This reassessment must involve a psychiatrist. Do not restart medications that were stopped before treatment without medical guidance, and do not assume that pre-treatment diagnoses and doses remain accurate. Ibogaine can produce durable changes in mood, anxiety, and depressive symptomatology that alter the medication picture (Noller et al., 2018).

Relapse Prevention Plan Formalization

By Day 90, you should have a written, specific relapse prevention plan that includes:

  • Named high-risk situations and specific response scripts
  • Emergency contacts (therapist, sponsor, trusted individual) with phone numbers written down — not only stored in a phone
  • Naloxone (Narcan) kit if opioids were part of your history — carried by you and known to people around you
  • A clear protocol for what to do if you slip: do not wait, do not minimize, contact support within the hour
  • Ongoing therapy schedule (at minimum biweekly after Day 90)

Lab Work and Medical Follow-Up

A follow-up appointment at 90 days with a physician who has your ibogaine treatment records should include:

  • Comprehensive metabolic panel (liver and kidney function)
  • Complete blood count
  • ECG if any cardiac symptoms have occurred or if you have cardiac history
  • Thyroid function (ibogaine can affect thyroid parameters in some individuals)
  • Review of any supplements or medications introduced during integration

Planning Beyond 90 Days

The research on ibogaine outcomes consistently identifies sustained aftercare as the primary predictor of durable remission (Brown & Alper, 2018). Plan explicitly for:

  • Ongoing therapy (minimum monthly, ideally biweekly for another 6 months)
  • Continuation in peer support community
  • Annual medical review
  • Awareness that major life stressors (job loss, relationship breakdown, bereavement) are high-risk relapse triggers at any point, not only in the first 90 days

Absolute Contraindications During the Integration Period

The following carry documented serious risk during the post-ibogaine window and should be avoided entirely unless under direct medical supervision with full knowledge of your ibogaine treatment:

  • MDMA / ecstasy: Serotonergic interactions with residual noribogaine; cardiac demand; risk of serotonin syndrome
  • Methamphetamine or cocaine: Cardiac stimulant load during conduction recovery period; high relapse entrenchment risk
  • Opioids at any pre-treatment dose: Eliminated tolerance; fatal overdose risk documented in post-ibogaine deaths (Alper et al., 2012)
  • MAOIs: Ibogaine itself has weak MAOI activity; combining with dietary MAOIs or MAOI medications risks hypertensive crisis and serotonin syndrome
  • Ketamine infusions: Glutamate system interactions; not recommended without expert oversight within the first 60 days
  • Lithium: Can lower seizure threshold when combined with ibogaine metabolites; restart only under psychiatric supervision
  • Tramadol: Opioid and serotonergic; seizure risk; CYP2D6 metabolism competition with noribogaine

Documented Consequences of Inadequate Integration

A 2012 case series by Alper et al. reviewing 19 ibogaine-associated fatalities found that many deaths occurred in the post-acute period, not during the experience itself — including fatal opioid overdoses in individuals who returned to drug use days to weeks after treatment with dramatically reduced tolerance. A 2018 New Zealand observational study (Noller et al.) found that ibogaine participants who received structured psychosocial aftercare had significantly better outcomes at 12-month follow-up than those who did not. The Multidisciplinary Association for Psychedelic Studies and the Global Ibogaine Therapy Alliance both explicitly require or strongly recommend structured integration support as part of any responsible treatment protocol.

Frequently Asked Questions

Not without medical supervision. SSRIs, SNRIs, and tricyclic antidepressants can all prolong the QTc interval and interact with the ibogaine metabolite noribogaine, which remains active for up to 96 hours post-dose. Additionally, some clinical protocols suggest that reintroducing SSRIs too early may blunt the neuroplastic benefits of treatment. A psychiatrist with knowledge of your ibogaine treatment should review your medication needs — ideally before Day 14 and with an ECG in hand. Do not restart medications independently.
The elevated mood experienced in the days to weeks after ibogaine — sometimes called the 'afterglow' or clinically referenced as an acute anti-depressant effect — is real but temporary and not a reliable indicator of long-term outcome. Research consistently shows that structured psychosocial support is the primary predictor of durable benefit (Noller et al., 2018; Brown & Alper, 2018). Feeling well is exactly when the therapeutic window is open and can be most effectively used. Skipping integration therapy because you feel good is analogous to stopping antibiotics because your fever broke — the underlying work is not complete.
There is no established safe timeline, and cannabis is not risk-free in the post-ibogaine context. Cannabis can destabilize mood, trigger anxiety or paranoia during the psychologically sensitive integration period, and — in individuals with vulnerability to psychosis — can contribute to cannabis-induced psychotic episodes, a risk that may be elevated when significant psychological material has been opened. Many integration clinicians recommend a minimum of 30 days of abstinence. More conservatively, the Global Ibogaine Therapy Alliance recommends abstaining from all psychoactive substances, including cannabis, for the full 90-day integration period. If cannabis is used for a documented medical condition, discuss this specifically with your integration therapist and prescribing physician.
Contact your integration therapist or a crisis line immediately — do not wait for a scheduled appointment. In the US, call or text 988 (Suicide and Crisis Lifeline) available 24/7. Suicidal ideation can emerge during integration for several reasons: unprocessed trauma surfaced by the experience, rebound depression as the acute afterglow fades (which can occur around weeks 3–6), or underlying mood disorder that was unmasked. This is a medical situation requiring same-day intervention. If you are in immediate danger, call 911 or go to an emergency department. Be honest with emergency providers about the ibogaine treatment — the information is necessary for your safety, and in most countries you cannot be criminally prosecuted for receiving treatment abroad.
Repeating a full ibogaine flood dose within 90 days is not supported by evidence and carries compounding cardiac risk. The QTc prolongation effects are cumulative with repeated dosing, and the neuroplastic window opened by the first session has not yet been fully consolidated. Some clinical protocols use low-dose ibogaine 'boosters' (typically 1–3 mg/kg versus flood doses of 10–25 mg/kg) to support integration, but these must be administered by medically qualified practitioners with cardiac monitoring — not self-administered. Micro- or mini-dosing protocols exist but are experimental and lack safety data in the post-flood context. Do not repeat treatment within 90 days without a full cardiac workup and the explicit guidance of an experienced ibogaine physician.
Look for licensed mental health professionals (psychologists, licensed clinical social workers, licensed professional counselors) who have specific training in psychedelic integration. Directories include the MAPS therapist directory, the Psychedelic Support network (psychedelic.support), and the Zendo Project referral network. The Global Ibogaine Therapy Alliance (GITA) maintains a list of vetted practitioners familiar specifically with ibogaine. When screening a therapist, ask directly: Have you worked with ibogaine patients before? Are you familiar with the cardiac and psychological risks of the post-treatment period? What is your training in trauma-informed care? A therapist without psychedelic-specific experience can still be helpful, but they should be willing to be briefed on ibogaine's specific effects and should not pathologize the content of the experience.

Key Sources

  • Alper, K.R., et al. (2012). Fatalities temporally associated with the ingestion of ibogaine. HEC Forum, 24(4), 255–294.
  • Bowen, S., et al. (2014). Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders. JAMA Psychiatry, 71(5), 547–556.
  • Brown, T.K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24–36.
  • Cotman, C.W., & Berchtold, N.C. (2002). Exercise: a behavioral intervention to enhance brain health and plasticity. Trends in Neurosciences, 25(6), 295–301.
  • Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. gita.org.
  • Glue, P., et al. (2015). Ascending-dose study of noribogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(2), 189–194.
  • He, D.Y., et al. (1997). Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. Journal of Neuroscience, 25(3), 619–628.
  • Kelly, J.F., et al. (2017). Prevalence and pathways of recovery from drug and alcohol problems in the United States population. Drug and Alcohol Dependence, 181, 162–169.
  • Koenig, X., et al. (2015). Anti-addiction drug ibogaine inhibits voltage-gated ionic currents. Addiction Biology, 19(4), 1–11.
  • Noller, G.E., et al. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37–46.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.